Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Saquinavir

FDA-approved product (capsule, oral), marketed as Fortovase, Invirase.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Saquinavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Saquinavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Saquinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.

    NCT00145561 · start 2005-08

    Registered record
    Registry ID
    NCT00145561
    Conditions
    HIV Infections
    Interventions
    Saquinavir and Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2008-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionSaquinavir and Ritonavir
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity

    NCT00477048 · start 2004-05

    Registered record
    Registry ID
    NCT00477048
    Conditions
    IDV Associated Nephrotoxicity
    Interventions
    Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2008-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIDV Associated Nephrotoxicity
    InterventionSaquinavir
    PhasePhase 2
    Registry statusCompleted

  • The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients

    NCT00400738 · start 2004-03

    Registered record
    Registry ID
    NCT00400738
    Conditions
    HIV Infections
    Interventions
    Saquinavir, lopinavir, ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2006-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionSaquinavir, lopinavir, ritonavir
    PhasePhase 2
    Registry statusCompleted

  • Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

    NCT00051831 · start 2003-10

    Registered record
    Registry ID
    NCT00051831
    Conditions
    HIV Infections
    Interventions
    Emtricitabine; Enfuvirtide; Ritonavir; Saquinavir; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-10
    Completion
    2008-05
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmtricitabine; Enfuvirtide; Ritonavir; Saquinavir +1 more
    PhaseNot applicable
    Registry statusCompleted

  • A PK and Salvage Study for Children With HIV-infection

    NCT00476359 · start 2003-10

    Registered record
    Registry ID
    NCT00476359
    Conditions
    HIV Infections
    Interventions
    Lopinavir/r plus saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2008-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLopinavir/r plus saquinavir
    PhasePhase 4
    Registry statusCompleted

  • Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

    NCT00056641 · start 2003-02-18

    Registered record
    Registry ID
    NCT00056641
    Conditions
    HIV Infections
    Interventions
    tipranavir; ritonavir; saquinavir; amprenavir; lopinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-02-18
    Completion
    Not recorded
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventiontipranavir; ritonavir; saquinavir; amprenavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

    NCT00050180 · start 2002-11-22

    Registered record
    Registry ID
    NCT00050180
    Conditions
    Healthy; HIV Infections
    Interventions
    Midazolam; Indinavir; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11-22
    Completion
    2007-08-24
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; HIV Infections
    InterventionMidazolam; Indinavir; Saquinavir
    PhasePhase 4
    Registry statusCompleted

  • Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

    NCT00039741 · start 2002-08

    Registered record
    Registry ID
    NCT00039741
    Conditions
    HIV Infections
    Interventions
    NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT); NNRTIs (EFV, NVP); PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2010-03
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT); NNRTIs (EFV, NVP); PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

    NCT00035932 · start 2001-11

    Registered record
    Registry ID
    NCT00035932
    Conditions
    HIV Infections
    Interventions
    Atazanavir + ritonavir + tenofovir + nucleoside; Atazanavir + saquinavir + tenofovir + nucleoside; Lopinavir/ritonavir + tenofovir + nucleoside
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2009-03
    Enrolment
    571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir + ritonavir + tenofovir + nucleoside; Atazanavir + saquinavir + tenofovir + nucleoside; Lopinavir/ritonavir + tenofovir + nucleoside
    PhasePhase 3
    Registry statusCompleted

  • Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

    NCT00038532 · start 2001-04

    Registered record
    Registry ID
    NCT00038532
    Conditions
    HIV Infections
    Interventions
    Amprenavir/ritonavir; Saquinavir/ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-04
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAmprenavir/ritonavir; Saquinavir/ritonavir; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

    NCT00005762 · start 2001-03

    Registered record
    Registry ID
    NCT00005762
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate; Efavirenz; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

    NCT00004584 · start 1999-12

    Registered record
    Registry ID
    NCT00004584
    Conditions
    HIV Infections
    Interventions
    Atazanavir; Ritonavir; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-12
    Completion
    2002-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir; Ritonavir; Saquinavir
    PhasePhase 2
    Registry statusCompleted

  • Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

    NCT02239835 · start 1999-12

    Registered record
    Registry ID
    NCT02239835
    Conditions
    HIV Infections
    Interventions
    Tipranavir (TPV) low dose; Tipranavir (TPV) high dose; Ritonavir low dose; Ritonavir high dose; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    1999-12
    Completion
    Not recorded
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir (TPV) low dose; Tipranavir (TPV) high dose; Ritonavir low dose; Ritonavir high dose +1 more
    PhasePhase 2
    Registry statusTerminated

  • Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

    NCT00003008 · start 1997-12-15

    Registered record
    Registry ID
    NCT00003008
    Conditions
    Sarcoma
    Interventions
    indinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir; saquinavir mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-12-15
    Completion
    Not recorded
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventionindinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

    NCT00000848

    Registered record
    Registry ID
    NCT00000848
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-10
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Saquinavir
    PhasePhase 2
    Registry statusCompleted